Skip to main content
Henan Lingrui Pharmaceutical Co., Ltd logo

Henan Lingrui Pharmaceutical Co., Ltd — Investor Relations & Filings

Ticker · 600285 ISIN · CNE000001501 LEI · 300300NNZECAUBZEA076 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,560 across all filing types
Latest filing 2026-05-21 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600285

About Henan Lingrui Pharmaceutical Co., Ltd

https://www.lingrui.com/

Henan Lingrui Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, with a primary focus on transdermal drug delivery systems. The company is a prominent producer of rubber plasters and external application medicines, notably its range of pain relief patches used for musculoskeletal and joint conditions. Its product portfolio extends to oral formulations, including capsules and tablets targeting cardiovascular health and inflammatory ailments. By integrating traditional medicinal principles with modern delivery technologies, the company provides a diverse array of therapeutic solutions. Its operations encompass the entire value chain from raw material processing to large-scale production and distribution, maintaining a significant presence in clinical and consumer healthcare markets through its specialized focus on external analgesic treatments.

Recent filings

Filing Released Lang Actions
羚锐制药第十届董事会第一次会议决议公告
Board/Management Information Classification · 92% confidence The document is the resolutions announcement from the company’s 10th Board of Directors first meeting, detailing the election of board committee members, the appointment of the chairman, general manager, vice-general managers, CFO, board secretary, and securities affairs representative. It is an announcement of changes in the company’s board composition and senior management positions. This falls under Board/Management Information (Code: MANG).
2026-05-21 Chinese
羚锐制药2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is the official announcement of the resolutions and detailed voting results from the company’s 2025 Annual General Meeting, including attendance, vote counts by shareholder class, and proposal outcomes. This matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 Chinese
羚锐制药关于选举第十届董事会职工代表董事的公告
Board/Management Information Classification · 85% confidence The document is an announcement by Henan Lingrui Pharmaceutical Co., Ltd. regarding the election of a new employee representative director to the company’s 10th Board. It provides details of the election process, the appointee’s qualifications, and effective term. This is a clear announcement of a board change rather than financial results, AGM materials, or regulatory filings, matching the Board/Management Information category.
2026-05-20 Chinese
羚锐制药关于会计师事务所2025年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (大华会计师事务所) for the 2025 fiscal year audit engagement with 河南羚锐制药股份有限公司. It details the qualifications, independence, quality management, work plan, and other aspects of the auditor's performance during the audit process. The document does not contain actual financial statements or substantive financial data but rather assesses the auditor's conduct and quality control related to the audit of the 2025 annual report. It is not the audit report itself, nor is it an annual report or interim report. The document is a standalone audit-related evaluation report, fitting the category of Audit Report / Information (AR). The document length is 3372 characters, which is not extremely short, and it contains detailed evaluation content rather than just an announcement or certification. Therefore, the best classification is AR with high confidence.
2026-04-27 Chinese
董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee of Henan Lingrui Pharmaceutical Co., Ltd. for the year 2025. It discusses the committee's activities, meetings, supervision of external and internal audits, review of financial reports, and internal control evaluations. The content focuses on the audit committee's performance and oversight responsibilities rather than presenting full financial statements or the entire annual report. The document length is 2517 characters, which is relatively short and more consistent with a committee report rather than a full Annual Report (10-K) or Audit Report (AR). It is not an announcement or certification but a substantive report on the audit committee's duties and findings for the year. This fits best under Audit Report / Information (AR), which includes standalone audit reports and related information excluding full annual reports.
2026-04-27 Chinese
羚锐制药审计报告
Regulatory Filings
2026-04-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.